Mor­phoSys out-li­cens­es two an­ti­bod­ies to se­cre­tive ARCH biotech as it push­es for­ward with lead Con­stel­la­tion work

Mor­phoSys is part­ner­ing and in­vest­ing in a se­cre­tive ARCH-backed biotech as it con­tin­ues re­or­ga­niz­ing the pipeline fol­low­ing a $1.7 bil­lion June 2021 buy­out of Con­stel­la­tion and sub­se­quent punt­ing of ear­ly-stage as­sets.

The Ger­man com­pa­ny will team up with ARCH’s Hu­man Im­munol­o­gy Bio­sciences, or HI­Bio for short, in a deal for two clin­i­cal pro­grams. Mor­phoSys will re­ceive a 15% eq­ui­ty stake in HI­Bio and net a $15 mil­lion up­front pay­ment, as well as be­come el­i­gi­ble for up to $1 bil­lion in mile­stone pay­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER